{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04648202",
            "orgStudyIdInfo": {
                "id": "FS120-19101"
            },
            "secondaryIdInfos": [
                {
                    "id": "2021-002820-19",
                    "type": "EUDRACT_NUMBER"
                },
                {
                    "id": "MK-3475-C82",
                    "type": "OTHER",
                    "domain": "Merck Sharp & Dohme LLC"
                },
                {
                    "id": "KEYNOTE-C82",
                    "type": "OTHER",
                    "domain": "Merck Sharp & Dohme LLC"
                }
            ],
            "organization": {
                "fullName": "invoX Pharma Limited",
                "class": "INDUSTRY"
            },
            "briefTitle": "FS120 Phase 1/1b Study in Patients With Advanced Malignancies",
            "officialTitle": "A Phase 1/1b Open-Label Study to Evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination With Pembrolizumab, in Subjects With Advanced Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "phase-study-in-patients-with-advanced-malignancies"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-11-18",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2026-03-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-03-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-11-23",
            "studyFirstSubmitQcDate": "2020-11-23",
            "studyFirstPostDateStruct": {
                "date": "2020-12-01",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-08",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-09",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "invoX Pharma Limited",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Merck Sharp & Dohme LLC",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a Phase 1/1b, multicenter, open label study to evaluate the Safety and Antitumor Activity of FS120, an OX40/CD137 Bispecific Antibody, Alone and in Combination with Pembrolizumab, in Subjects with Advanced Malignancies"
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Cancer",
                "Metastatic Cancer"
            ],
            "keywords": [
                "Immuno-oncology",
                "Bispecific antibody",
                "Dose escalation",
                "Cohort expansion",
                "OX40",
                "CD137 (4-1BB)",
                "invoX",
                "Pembrolizumab",
                "PD-1"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 277,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "FS120",
                    "type": "EXPERIMENTAL",
                    "description": "Open-label study where FS120 will be administered as monotherapy or in combination with pembrolizumab in dose escalation and expansion cohorts",
                    "interventionNames": [
                        "Drug: FS120"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "FS120",
                    "description": "Dosing of participants with FS120 or the combination pembrolizumab will occur intravenously (IV), at a fixed dose in treatment cycles once every 4 weeks (Q4W) or once every 3 weeks (Q3W) until confirmed progressive disease (CPD)/immune-confirmed progressive disease (iCPD) or unacceptable toxicity.",
                    "armGroupLabels": [
                        "FS120"
                    ],
                    "otherNames": [
                        "Pembrolizumab (KEYTRUDA\u00ae)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence, severity, and duration of adverse events (AEs), serious adverse events (SAEs) and dose limiting toxicities (DLTs)",
                    "description": "Safety and tolerability will be evaluated by collection of AEs, SAEs and DLTs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Determination of a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D)",
                    "description": "Toxicity will be evaluated according to the NCI CTCAE Version 5.0.",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Measurable disease\n* Eastern Cooperative Oncology Group Performance Status 0-1.\n* Highly effective contraception if risk of conception exists\n* A female subject is eligible if not pregnant, not breastfeeding, not a woman of childbearing potential (WOCBP) or is a WOCBP that uses highly effective contraception\n* Subjects with HIV who are healthy and how a low risk of acquired immunodeficiency syndrome related outcomes\n* For combination part: Subjects must have histologically confirmed locally advanced, unresectable or metastatic solid tumours where there is regulatory approval for use of pembrolizumab as a monotherapy agent\n\nExclusion Criteria:\n\n* Prior systemic anticancer therapy within 28 days or 5- half-lives, whichever is shorter, before the first dose of study drug.\n* Prior therapy with any OX40 agonist, CD137 (4-1BB) agonist, CD40 agonist, GITR, or CD27 targeting therapy (single agent or combination).\n* Prior radiotherapy within 2 weeks of start of study treatment.\n* HIV infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.\n* Uncontrolled central nervous system (CNS) metastases and/or carcinomatous meningitis, primary CNS tumours, or solid tumours with CNS metastases as the only measurable disease.\n* Prior history of any grade \u22653 immune-related AE (irAE) that has not improved to grade \u22641; any grade \u22653 irAE that resulted in discontinuation of treatment, significant (grade \u22653 NCI CTCAE Version 5.0) treatment-related cytokine release syndrome.\n* Use of immunosuppressive agents, hypersensitivity or intolerance to monoclonal antibodies or their excipients, persistent grade \u22651 NCI CTCAE Version 5 toxicity related to prior therapy or any condition that would significantly impair and/or prohibit the participant's participation in the study, as per the investigator's judgement.\n* Vaccination with a live vaccine within 30 days before first dose of study drug.\n* Participants with a known additional malignancy that is progressing or has required active treatment in the past 3 years.\n* Participants with severe hypersensitivity (\u2265Grade 3) to pembrolizumab and/or any of its excipients.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "invoX Clinical Trials",
                    "role": "CONTACT",
                    "phone": "+44 2038 820886",
                    "email": "info@invoxpharma.com"
                }
            ],
            "locations": [
                {
                    "facility": "Yale University",
                    "status": "COMPLETED",
                    "city": "New Haven",
                    "state": "Connecticut",
                    "zip": "06511",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.30815,
                        "lon": -72.92816
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "COMPLETED",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics (START)",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                },
                {
                    "facility": "Huntsman Cancer Institute, University of Utah",
                    "status": "RECRUITING",
                    "city": "Salt Lake City",
                    "state": "Utah",
                    "zip": "84112",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 40.76078,
                        "lon": -111.89105
                    }
                },
                {
                    "facility": "NEXT Oncology, Hospital Quironsalud Barcelona",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08023",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario Vall d'Hebron",
                    "status": "RECRUITING",
                    "city": "Barcelona",
                    "zip": "08035",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 41.38879,
                        "lon": 2.15899
                    }
                },
                {
                    "facility": "Hospital Universitario Fundacion Jimenez Diaz",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28040",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Universitario 12 de Octubre",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28041",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Hospital Clinico Universitario de Valencia",
                    "status": "RECRUITING",
                    "city": "Valencia",
                    "zip": "46010",
                    "country": "Spain",
                    "geoPoint": {
                        "lat": 39.46975,
                        "lon": -0.37739
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Metastatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M20194",
                    "name": "Antibodies, Bispecific",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}